| Identification | Back Directory | [Name]
EGFR-IN-8 | [CAS]
2407957-87-1 | [Synonyms]
EGFR-IN-8
inhibit,Epidermal growth factor receptor,EGFR IN 8,ErbB-1,HER1,Inhibitor,c-Met/HGFR,EGFRIN8,EGFR
N-(3-Chloro-4-(5-(3-(3-(4-(cyclopropanecarboxamido)-3-(trifluoromethyl)phenyl)ureido)phenyl)-1,2,4-oxadiazol-3-yl)phenyl)nicotinamide
3-Pyridinecarboxamide, N-[3-chloro-4-[5-[3-[[[[4-[(cyclopropylcarbonyl)amino]-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-1,2,4-oxadiazol-3-yl]phenyl]- | [Molecular Formula]
C32H23ClF3N7O4 | [MDL Number]
MFCD32201095 | [MOL File]
2407957-87-1.mol | [Molecular Weight]
662.02 |
| Hazard Information | Back Directory | [Uses]
EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC[1]. | [in vivo]
EGFR-IN-8 (oral gavage; 50 and 150?mg/kg; once daily; 20 days) exhibits a dose-dependent suppression (29% and 60%, respectively) of H1975 xenograft tumor growth at 50 and 150?mg/kg[1]. | Animal Model: | Nude mice H1975 xenograft tumor model[1] | | Dosage: | 50 and 150?mg/kg | | Administration: | Oral gavage; 50 and 150?mg/kg; once daily; 20 days | | Result: | Inhibited H1975 xenograft tumor growth. |
| [References]
[1] Dokla EME, et al. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC. Eur J Med Chem. 2019 Aug 9;182:111607. DOI:10.1016/j.ejmech.2019.111607 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|